Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain

NCT ID: NCT05851768

Last Updated: 2024-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-15

Study Completion Date

2024-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Postoperative pain management is considered an integral part of perioperative care in patients undergoing thoracotomy. In order to reduce these complications, multiple regional techniques have been developed for thoracotomy including Intercostal nerve block, Erectospinae plane block and serratus block. Multiple adjuvants have been used in regional analgesia including adrenaline,clonidine,magnesium sulphate,dexmedatomidine and opoids.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Investigators
Double blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Erector spinae plane block with 0.25% bupivacaine

Patients will receive ultrasound guided ESPB with 0.25% bupivacaine

Group Type ACTIVE_COMPARATOR

Bupivacaine

Intervention Type DRUG

Bupivacaine 0.25%

Erector spinae plane block with 0.25% bupivacaine and Magnesium

Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and magnesium

Group Type EXPERIMENTAL

Bupivacaine + Magnesium

Intervention Type DRUG

Bupivacaine 0.25% + Magnesium

Erector spinae plane block with 0.25% bupivacaine and Dexmedetomidine

Patients will receive ultrasound guided ESPB with 0.25% bupivacaine and dexmedetomidine

Group Type EXPERIMENTAL

Bupivacaine + Dexmedetomidine

Intervention Type DRUG

Bupivacaine 0.25% + Dexmedetomidine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine

Bupivacaine 0.25%

Intervention Type DRUG

Bupivacaine + Magnesium

Bupivacaine 0.25% + Magnesium

Intervention Type DRUG

Bupivacaine + Dexmedetomidine

Bupivacaine 0.25% + Dexmedetomidine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 65 years.
* Male and female sexes.
* ASA I-II.,III
* Cancer patients undergoing thoracotomy incisions
* Body mass index (BMI) from 18.5 to 30 kg/m2

Exclusion Criteria

* Patient refusal
* Known allergy to any of the used drugs
* Low platelet count, any coagulation defect
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute, Egypt

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Walaa Youssef Elsabeeny

Assistant professor of Anesthesia and Pain management

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Walaa Y Elsabeeny, MD

Role: PRINCIPAL_INVESTIGATOR

Assistant professor of Anesthesia and Pain Management, National Cancer Institute, Cairo University

Ahmed A Mohamed, MD

Role: STUDY_DIRECTOR

Professor of Anesthesia,Surgical intensive care and Pain management,Faculty of medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Walaa Y Elsabeeny

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Walaa Y Elsabeeny, MD

Role: CONTACT

01007798466 ext. +2

Ahmed A Mohamed, MD

Role: CONTACT

01272222923 ext. +2

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Walaa Y Elsabeeny, MD

Role: primary

+201007798466

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N-80-2022/NSC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.